文献速递心外重症与机械循环支持

成人终末期心力衰竭左心室辅助装置随机试验与观察性研究的网状Meta分析

A network meta-analysis of randomized trials and observational studies on left ventricular assist devices in adult patients with end-stage heart failure.
PubMed 文献 · Eur J Cardiothorac Surg · 2019-01-01

该网状Meta分析纳入4项随机临床试验和4项观察性研究、共2248例成人终末期心力衰竭患者,比较左心室辅助装置(LVAD)与药物治疗及不同LVAD间的死亡、卒中与出血等结局。以HeartMate XVE/VE为基准,各LVAD的生存率均优于药物治疗,但新型LVAD之间无显著差异;新一代装置在出血、装置血栓等不良事件上优于老一代装置。

要点

  • 各LVAD生存率均显著优于药物治疗,新型LVAD之间无显著差异
  • HeartMate 3与HeartWare在出血、装置血栓、肝肾功能障碍等方面优于老一代装置
  • 作者认为需进一步技术改进以改善决策与临床结局

核心结论

  • 在终末期心力衰竭的管理中,与药物治疗相比,LVAD在生存率方面提供显著改善,但LVAD之间不存在显著差异。
  • 尽管不良事件随时间减少,进一步的技术改进对完善该技术、更好地支持决策和改善临床结局仍至关重要。

研究设计与样本

  • 研究类型为网状Meta分析,纳入4项随机临床试验和4项观察性研究,共2248例成人终末期心力衰竭患者。
  • 在多个数据库中检索相关研究,提取死亡、卒中和出血等结局,采用网状Meta分析计算相对风险及95%CI与P-score(数值越高提示治疗越优)。

主要发现

  • 以HeartMate XVE/VE为基准,所有LVAD的生存率均显著优于药物治疗,新型LVAD之间无显著差异。
  • 死亡相对风险:HeartMate II为0.79(95%CI 0.60-1.04;P-score 0.89),HeartWare为0.85(95%CI 0.62-1.17;P-score 0.64),HeartMate 3为0.88(95%CI 0.59-1.31;P-score 0.60),药物治疗为1.48(95%CI 1.21-1.80;P-score 0.01)。
  • 在出血、装置血栓、肝功能障碍、肾功能障碍、呼吸功能障碍、右心室衰竭和脓毒症等结局上,新一代装置(HeartMate 3和HeartWare)优于老一代装置,且彼此间存在显著差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The use of left ventricular assist devices (LVADs) is an approved treatment option for end-stage heart failure. Several devices have been developed over the years, including 2 newer ones (HeartMate 3 and HeartWare), but an overall comparative analysis has never been performed. We conducted a network meta-analysis of randomized trials on LVAD for adults with end-stage heart failure. METHODS: Pertinent studies were searched in several databases. Selected outcomes were extracted, including death, stroke and bleeding. Incident relative risks were computed with network meta-analysis with 95% confidence intervals (CIs) and P-scores (with highest values indicating the best therapy). RESULTS: Four randomized clinical trials and 4 observational studies were identified, totalling 2248 patients. Using HeartMate XVE/VE as the benchmark, all LVADs provided a significant better outcome for survival rate in comparison with medical therapy, without significant differences among newer LVADs. The relative risk for death was 0.79 (95% 0.60-1.04; P-score 0.89) for HeartMate II, 0.85 (95% CI 0.62-1.17; P-score 0.64) for HeartWare, 0.88 (95% CI 0.59-1.31; P-score 0.60) for HeartMate 3 and 1.48 (95% CI 1.21-1.80; P-score 0.01) for medical management. While appraising other outcomes, new generation devices (HeartMate 3 and HeartWare) proved better than older generation devices for bleeding, device thrombosis, hepatic dysfunction, renal dysfunction, respiratory dysfunction, right ventricular failure and sepsis with significant differences among them. CONCLUSIONS: In the management of end-stage heart failure, LVADs provided significant improvement in terms of survival rate compared to medical therapy, but no significant differences exist among LVADs. Despite the reduction of adverse events over time, further technological refinements will be crucial to improve this technology to better address decision-making and to improve clinical outcomes.

来源:Eur J Cardiothorac Surg,查看原文。版权归原作者所有。

引用

  1. Cavarretta E, Marullo AGM, Sciarretta S, et al. A network meta-analysis of randomized trials and observational studies on left ventricular assist devices in adult patients with end-stage heart failure. Eur J Cardiothorac Surg. 2019. PMID: 30137270. doi:10.1093/ejcts/ezy285

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。